INNOVENT'S PARTNER OLLIN BIOSCIENCES ANNOUNCES OVERSUBSCRIBED $330 MILLION SERIES B FINANCING TO ADVANCE GLOBAL PHASE 3 DEVELOPMENT OF IBI324 (OLN324) IN DME AND WET AMD; STUDIES COMMENCING IN SECOND HALF OF 2026

Reuters · 1d ago

Please log in to view news